Leeds, UK, July 26, 2021 – 4D pharma plc (AIM: DDDD, NASDAQ, LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived
4d Pharma PLC (DDDD.L) Publication – LBP improves activity of CAR-T
4D pharma Announces Publication of Preclinical Research Showing Single Strain Megasphaera massiliensis improves activity of CAR-T
4d Pharma PLC (DDDD.L) Conference presentation on LBP Manufacturing
4D pharma to Present at the Microbiome Movement Drug Development Summit
4d Pharma PLC (DDDD.L) Asthma trial Part A enrollment and program update
4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provides Program Update
4d Pharma PLC (DDDD.L) Update on Data for Phase II Study of Blautix
4D pharma Presents Additional Positive Results of Phase II Study of Blautix® for the Treatment of Irritable Bowel Syndrome
4d Pharma PLC (DDDD.L) Presentation of Blautix IBS Phase II at DDW 2021
4D pharma to Present Additional Data from Phase II Study of Blautix for the Treatment of Irritable Bowel Syndrome at Digestive Disease Week (DDW) 2021
4d Pharma PLC (DDDD.L) collaborates with Parkinson’s UK to establish Patient Advisory Board
Leeds, UK, April 19, 2021 – 4D pharma plc (AIM: DDDD; NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) – a novel class of drug
4d Pharma PLC (DDDD.L) Participation in Jefferies Therapeutics Summit
4D pharma to Participate in Jefferies Microbiome-Based Therapeutics Summit
4d Pharma PLC (DDDD.L) Completion of Merger
Completion of Merger with Longevity Acquisition Corporation and admission of American Depositary Shares to trading on NASDAQ
4d Pharma PLC (DDDD.L) Completion of Merger
Completion of Merger with Longevity Acquisition Corporation and admission of American Depositary Shares to trading on NASDAQ
4d Pharma PLC (DDDD.L) Appoints Paul Maier to the Board as NED
Leeds, UK, March 1, 2021 , – 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) – a novel class of drug derived